Hemosol B0

Hemosol B0 is an intravenous solution containing calcium, lactic acid, magnesium, sodium, chloride ion, and hydrogen carbonate. It is supplied in a sterile liquid form for use in haemodialysis and other intravenous applications within the European market. The formulation is designed to help maintain electrolyte balance during renal replacement therapy.

Hemosol B0 is employed primarily in settings where electrolyte management is critical, such as during haemodialysis procedures. It may also be used in other clinical situations that require controlled infusion of electrolytes.

- Supports electrolyte homeostasis during haemodialysis sessions. - Provides calcium and magnesium supplementation for patients with low serum levels. - Assists in correcting acid‑base disturbances in renal failure. - Used as a component of dialysis fluid mixes to tailor electrolyte composition. - May be administered intravenously in acute care when rapid electrolyte correction is needed.

Side effects of Hemosol B0 are generally related to its electrolyte composition and the rate of infusion. Most reactions are mild and reversible, but clinicians should monitor patients for any adverse signs.

Common: - Mild nausea or vomiting. - Transient headache. - Local irritation at the infusion site. - Mild hypotension due to rapid infusion. - Temporary changes in serum calcium or magnesium levels.

Serious: - Severe hypercalcemia or hypermagnesemia. - Cardiac arrhythmias linked to electrolyte imbalance. - Anaphylactic reaction to solution components. - Metabolic alkalosis from excess bicarbonate. - Acute pulmonary edema if volume overload occurs.

When using Hemosol B0, clinicians should consider patient-specific factors and monitor relevant clinical parameters. Proper handling and administration techniques help minimize risks.

- Verify serum electrolyte levels before and during infusion. - Adjust infusion rate to avoid rapid shifts in calcium or magnesium. - Use caution in patients with cardiac disease or arrhythmias. - Monitor acid‑base status, especially in patients prone to metabolic alkalosis. - Assess for signs of fluid overload in patients with compromised cardiac or renal function. - Ensure compatibility with other intravenous solutions to prevent precipitation.

Hemosol B0 may interact with other medications or solutions that affect electrolyte balance or acid‑base status. Awareness of these interactions helps prevent complications.

Avoid: - Concurrent infusion of calcium‑containing medications that could cause hypercalcemia. - Use with high‑dose magnesium supplements, which may lead to toxicity. - Mixing with acidic solutions that could precipitate calcium salts.

Use with caution: - Loop diuretics, which can alter calcium and magnesium excretion. - ACE inhibitors or ARBs, which may affect potassium and sodium balance. - Sodium bicarbonate therapy, as both contain bicarbonate. - Blood pressure medications, due to potential changes in vascular tone from electrolyte shifts.